Ironwood Pharmaceuticals, Inc. Class A (IRWD)

In July 2025, Ironwood Pharmaceuticals' shares dropped significantly after a revenue miss in Q1 2025 due to a timing shift in rebates related to Linzess, leading to analyst downgrades. In November 2025, the stock increased despite news of CMS cutting Linzess's list price from 2027, as the market viewed the cuts as less severe than expected. In January 2026, Ironwood maintained its FY 2025 financial guidance and announced FY 2026 guidance, expecting higher net sales for LINZESS due to a lowered list price effective January 1, 2026. On February 6, 2026, the stock price gained 2.47%, but had fallen 12.81% over the prior 10 days.

While explicit demand seasonality is not detailed, Ironwood reported a 12% year-over-year increase in total LINZESS prescription demand in Q3 2025. The lowering of the LINZESS list price effective January 1, 2026, is a strategic move to support ongoing patient access and is expected to result in higher net sales in 2026. This suggests consistent demand for LINZESS, with pricing adjustments to optimize market access and sales.

Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases. Their main product is LINZESS® (linaclotide) for irritable bowel syndrome with constipation or chronic idiopathic constipation. They are also developing apraglutide for short bowel syndrome and have a pipeline targeting GI motility, inflammation, and neurological conditions.

Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, and has operations in Basel, Switzerland. They conduct research and development in the U.S. and collaborate with global partners to expand into European, Canadian, and other international markets. LINZESS is commercialized in the United States and Mexico as Linzess, and as Constella in Europe, Canada, Japan, and China.

In the past year, Ironwood Pharmaceuticals has received a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.63. The company's MarketRank™ score indicates it performed better than 55% of companies evaluated by MarketBeat. In April 2025, the stock plummeted after Citizens JMP downgraded the stock due to the FDA requiring a confirmatory Phase 3 trial for apraglutide. The significant Q1 2025 revenue miss also negatively affected the company's standing.

Ironwood Pharmaceuticals' ownership is distributed among institutional investors (31.18%), insiders (13.03%), and public companies/individual investors (55.78%). Major institutional shareholders include Armistice Capital, Llc, Vanguard Group Inc., Sarissa Capital Management LP, and BlackRock, Inc. Alexander Denner owns the most shares of Ironwood Pharma.